Variation of the N-acetyltransferase 2 gene in a Romanian and a kyrgyz population

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 1, 2006, Pages 138-141

  Rabstein, Sylvia ^a   Unfried, Klaus ^b   Ranft, Ulrich ^b   Illig, Thomas ^c   Kolz, Melanie ^c   Rihs, Hans Peter ^a   Mambetova, Chinara ^d   Vlad, Mariana ^e   Brüning, Thomas ^a   Pesch, Beate ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d Kyrgyz Scientific Centre of Hematology   (Kyrgyzstan)

^e Professor Iuliu Moldovan Institute of Public Health Cluj Napoca   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; GENE PRODUCT; NAT2 PROTEIN, HUMAN;

ACETYLATION; ALLELISM; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; ENVIRONMENTAL EXPOSURE; ETHNIC DIFFERENCE; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; KYRGYZSTAN; MAJOR CLINICAL STUDY; MALE; NAT2 GENE; OCCUPATIONAL EXPOSURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ROMANIA; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN; CAUCASIAN; GENETIC PREDISPOSITION; GENETICS; GENOTYPE;

ACETYLATION; ARYLAMINE N-ACETYLTRANSFERASE; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KYRGYZSTAN; POLYMORPHISM, SINGLE NUCLEOTIDE; ROMANIA; VARIATION (GENETICS);

EID: 33645456098     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0256     Document Type: Article

References (24)

1. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000;9:29-42.
2. Packer BR, Yeager M, Staats B, et al. SNP500Cancer: a public resource for sequence validation and assay development for generic variation in candidate genes. Nucleic Acids Res 2004;32:D528-32.
3. Hinds DA, Stuve LL, Nilsen GB, et al. Whole-genome patterns of common DNA variation in three human populations. Science 2005;307:1072-9.
4. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001;10:1239-48.
5. Ranft U, Pesch B, Vogt A. Gold Extraction in Central and Eastern Europe (CEE) and the Commonwealth of Independent States (CIS)-health and environmental risks. Luxembourg: International Center for Studies and Research in Biomedicine; 2005.
6. Weidinger S, Klopp N, Wagenpfeil S, et al. Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults. J Med Genet 2004;41:658-63.
7. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
8. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9.
9. Roche Diagnostics. User manual RealArt™ NAT2 LC-PCR Kit. 2004.
10. Deitz AC, Rothman N, Rebbeck TR, et al. Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1543-6.
11. Cascorbi I, Roots I. Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics 1999;9:123-7.
12. Agundez JA, Olivera M, Martinez C, Ladero JM, Benitez J. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996;6:423-8.
13. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581-92.
14. Xie HG, Xu ZH, Ou-Yang DS, et al. Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. Pharmacogenetics 1997;7:503-14.
15. Delomenie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM. Genotyping of the polymorphic iV-aceryltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics 1996;6:177-85.
16. Jorge-Nebert LF, Eichelbaum M, Griese EU, Inaba T, Arias TD. Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine. Pharmacogenetics 2002;12:39-48.
17. Sekine A, Saito S, Iida A, et al. Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1 and L1CAM in the Japanese population. J Hum Genet 2001;46:314-9.
18. Lin HJ, Han Ch, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994;4:125-34.
19. Vineis P, Marinelli D, Autrup H, et al. Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev 2001;10:1249-52.
20. Marcus PM, Vineis P, Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 2000;10:115-22.
21. Zhao B, Seow A, Lee EJ, Lee HP. Correlation between acetylation phenotype and genotype in Chinese women. Eur J Clin Pharmacol 2000; 56:689-92.
22. Gross M, Kruisselbrink T, Anderson K, et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 1999;8:683-92.
23. O'Neil WM, Drobitch RK, MacArthur RD, et al. Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics 2000; 10:171-82.
24. Rothman N, Stewart WF, Caporaso NE, Hayes RB. Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons. Cancer Epidemiol Biomarkers Prev 1993;2:299-303.